MoonLake Immunotherapeutics (MLTX) Change in Accured Expenses (2021 - 2026)

MoonLake Immunotherapeutics' Change in Accured Expenses history runs 6 years deep, the most recent figure standing at $7.1 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 557.78% year-over-year to $7.1 million; the TTM figure through Mar 2026 stood at $11.3 million (up 75.55% YoY), while the FY2025 annual figure was $2.6 million, down 49.87% from the prior year.
• Change in Accured Expenses was $7.1 million for Q1 2026 at MoonLake Immunotherapeutics, up from -$6.9 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $12.9 million in Q3 2025 to a low of -$6.9 million in Q4 2025.
• Historically, Change in Accured Expenses has averaged $1.0 million across 5 years, with a median of $1.4 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Change in Accured Expenses tumbled 18799.85% in 2022, then surged 557.78% in 2026.
• A 5-year view of Change in Accured Expenses shows it stood at $2.2 million in 2022, then grew by 28.06% to $2.9 million in 2023, then soared by 45.51% to $4.2 million in 2024, then slumped by 265.24% to -$6.9 million in 2025, then soared by 203.28% to $7.1 million in 2026.
• The last three Change in Accured Expenses figures came in at $7.1 million (Q1 2026), -$6.9 million (Q4 2025), and $12.9 million (Q3 2025), per Business Quant data.